Eisai finds an exit from Aduhelm, with small royalties if it ever nabs coverage

Zachary Brennan

Senior Editor

With less than a month to go to the final national coverage determination from CMS, Biogen’s Japanese partner Eisai is essentially cutting its losses on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eisai finds an exit from Aduhelm, with small royalties if it ever nabs coverage

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Major FDA staff cuts would slow drug reviews, experts say

Updated: Bay Area biotech VC to shut down 15 months after launch, sources say, after key investor pulls out

Senators ask FDA to dig into 'misleading' Super Bowl ad from Hims

Bain buys Mitsubishi Tanabe Pharma in $3.3B bet on Japan

Roche heads to FDA with Gazyva results in a form of lupus

A fourth person receives gene-edited pig kidney, first in three-person study

Ei­sai finds an ex­it from Aduhelm, with small roy­al­ties if it ever nabs cov­er­age

Senior Editor

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Eisai finds an exit from Aduhelm, with small royalties if it ever nabs coverage